Culmerciclib rechallenge for HR+ HER2- breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18-75.
- Your breast cancer is HR-positive and HER2-negative, and has spread to other parts of the body or come back after initial treatment.
- You have already tried a CDK4/6 inhibitor with hormone therapy, and it stopped working.
- You have at least one tumor that can be measured on a scan (not in the brain).
- You do not have active brain metastases or other serious health conditions that would make treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called Culmerciclib for women with a certain type of advanced breast cancer that has both hormone receptors and HER2. It’s for patients whose cancer has been stable on at least 4 cycles of prior therapy.
This trial tests adding a new study drug (culmerciclib) to standard hormone therapy and HER2-targeted therapy given before surgery for early-stage breast cancer. The goal is to shrink the tumor and improve the chance of a successful surgery.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
This trial tests a new combination of drugs for advanced breast cancer that is both hormone receptor-positive (HR+) and HER2-positive. The treatment combines fulvestaciclib (a CDK4/6 inhibitor) with anti-HER2 therapy and endocrine therapy, aiming to slow or stop cancer growth. It may be an option if you have not yet had treatment for advanced disease.
This trial tests a new pill (M1774) combined with a hormone therapy called fulvestrant for people with advanced hormone-receptor-positive, HER2-negative breast cancer that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The study focuses on people with certain genetic markers in their tumor, hoping the combination will work better than current options.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.